Robert A. Blake
Genentech · 76 works · 6,755 citations · h-index 28
Top works
- In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.
- A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo.
- SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors.
- SU6656, a Selective Src Family Kinase Inhibitor, Used To Probe Growth Factor Signaling
- Collagen stimulates tyrosine phosphorylation of phospholipase C‐γ2 but not phospholipase C‐γ1 in human platelets
- Potent and selective inhibitors of the Met [hepatocyte growth factor/scatter factor (HGF/SF) receptor] tyrosine kinase block HGF/SF-induced tumor cell growth and invasion.
- A Novel Tankyrase Small-Molecule Inhibitor Suppresses APC Mutation–Driven Colorectal Tumor Growth
- USP7 small-molecule inhibitors interfere with ubiquitin binding
- Src promotes PKCdelta degradation.
- A cellular model for sporadic ALS using patient-derived induced pluripotent stem cells
- Src family kinase activity is required for signal tranducer and activator of transcription 3 and focal adhesion kinase phosphorylation and vascular endothelial growth factor signaling in vivo and for anchorage-dependent and -independent growth of human tumor cells.
- Therapeutic Ligands Antagonize Estrogen Receptor Function by Impairing Its Mobility
- Antibody Conjugation of a Chimeric BET Degrader Enables in vivo Activity
- GDC-9545 (Giredestrant): A Potent and Orally Bioavailable Selective Estrogen Receptor Antagonist and Degrader with an Exceptional Preclinical Profile for ER+ Breast Cancer
- Antibody-Mediated Delivery of Chimeric BRD4 Degraders. Part 2: Improvement of In Vitro Antiproliferation Activity and In Vivo Antitumor Efficacy
- Fcγ receptor II stimulated formation of inositol phosphates in human platelets is blocked by tyrosine kinase inhibitors and associated with tyrosine phosphorylation of the receptor
- The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer
- Antibody-Mediated Delivery of Chimeric BRD4 Degraders. Part 1: Exploration of Antibody Linker, Payload Loading, and Payload Molecular Properties
- Design and synthesis of aminopropyl tetrahydroindole-based indolin-2-ones as selective and potent inhibitors of Src and Yes tyrosine kinase
- Monomeric Targeted Protein Degraders